Current Treatments of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitors-2020 Update.
Ontology highlight
ABSTRACT: During the last 20 years, chemotherapy has improved survival rates of colorectal cancer (CRC). However, the majority of metastatic cases do not respond to or progress after first line conventional chemotherapy and contribute to the fatalities of patients with CRC. Insights into the immune contexture of the tumor microenvironment (TME) have enabled the development of new systemic treatments that boost the host immune system against the tumor-the immune checkpoint inhibitors (ICI). These promising drugs have already shown astonishing efficacies in other cancer types and have raised new hope for the treatment of metastatic CRC (mCRC). In this review, we will summarize the results of the clinical trials that led to their accelerated approval by the U.S. Food and Drug Administration (FDA) in 20
SUBMITTER: Jung G
PROVIDER: S-EPMC7694085 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA